Personalized Dosing and Genetic Insights for Your Situation The PlexusDx Precision Peptide Genetic Test analyzes GLP1R (rs6923761) variants that relate to GLP-1 and related signaling pathways
Combination Therapy Enters the Competitive Field CagriSema (Novo Nordisk), a once weekly injectable combination of semaglutide and the longacting amylin analogue cagrilintide, is expected to receive FDA approval by late 2026
While various GLP-1 RAs such as Semaglutide (Wegovy, Ozempic), Dulaglutide (Trulicity), Lixisenatide (Adlyxin), and Tirzepatide (Mounjaro, Zepbound) are commonly prescribed, their specific pharmacokinetics and effects on gastric motility vary, adding complexity to perioperative care (Almandoz et al
It is for informational purposes only and does not replace medical care and advice from a healthcare provider
Additionally, semaglutide acts on receptors in the brain to reduce appetite and promote satiety, contributing to its weight loss effects
This information is for educational purposes and not meant to replace professional medical advice.
